The Medical Letter on Drugs and Therapeutics
Tesamorelin (Egrifta) for HIV-Associated Lipodystrophy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved tesamorelin (Egrifta – EMD Serono), an injectable synthetic analog of growth-hormone-releasing factor (GRF), for reduction of excess abdominal fat in patients with lipodystrophy associated with HIV infection. Growth hormone (somatropin – Serostim; EMD Serono) has been available for years for treatment of HIV wasting.

LIPODYSTROPHY — HIV lipodystrophy is characterized by loss of subcutaneous fat in some areas (limbs, face, buttocks) and accumulation of fat in other areas (abdominal viscera, upper back), commonly accompanied by the metabolic syndrome. Visceral abdominal fat is both a risk factor for cardiovascular disease and diabetes mellitus and a serious cosmetic problem in HIVinfected patients.1

MECHANISM OF ACTION — GRF, more commonly known as growth-hormone-releasing hormone (GHRH), stimulates production and release ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tesamorelin (Egrifta) for HIV-Associated Lipodystrophy
Article code: 1363b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian